Go Back   HER2 Support Group Forums > Articles of Interest
Register Gallery FAQ Members List Calendar Search Today's Posts Mark Forums Read

Thread Tools Display Modes
Old 06-19-2003, 05:42 AM   #1
Posts: n/a
I should note that it is often times important to review the actual clinical study relating to a medical issue rather than rely upon outside reporting of the study. This is one such case. The cancerfacts article regarding the occurrence of CNS metastates with respect to women on Herceptin is confusing. However the conclusion of the actual medical study appears sound. Accordingly I have provided a cross-link to the actual medical study abstract.

The conclusion of the study is as follows:

Metastatic breast carcinoma to the CNS is common among patients receiving trastuzumab-based therapy including patients responding to therapy outside the CNS. This may be due either to predilection for the CNS by HER-2-positive tumor cells and/or poor penetration of the CNS by trastuzumab or to improved visceral disease control leading to a longer life and onset of late tumor spread to the CNS. Efforts to characterize other risk factors for development of CNS disease optimal screening algorithms and new treatment strategies may be warranted.
  Reply With Quote

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is On

Forum Jump

All times are GMT -7. The time now is 09:30 PM.

Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2020, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007
free webpage hit counter